New diabetes drug shows promise in first human tests
NCT ID NCT05363774
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tested a new medicine, NNC0519-0130, in people for the first time. It aims to lower blood sugar and reduce appetite, which could help manage type 2 diabetes and obesity. The trial involved 161 healthy volunteers, overweight individuals, and people with type 2 diabetes, receiving either the drug or a placebo as injections or tablets. The main goal was to check safety and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS (DIABETES MELLITUS, TYPE 2) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novo Nordisk Investigational Site
Søborg, 2860, Denmark
-
Profil GmbH & Co. KG
Mainz, 55116, Germany
-
Profil Institut für Stoffwechselforschung GmbH
Neuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.